Engelsk titel: Biological treatment of multiple sclerosis
Läs online
Författare:
Soelberg Sörensen P
;
Sellebjerg F
Email: pss@rh.dk
Språk: Dan
Antal referenser: 10
Dokumenttyp:
Artikel
UI-nummer: 08061248
Sammanfattning
In 1996 interferon (IFN)ß was the first biopharmaceutical product to be approved for the treatment of relapsing-remitting multiple sclerosis (MS). In 2006 the more potent monoclonal antibody natalizumab was approved. Presently, a number of monoclonal antibodies are being studied, including alemtuzumab, daclizumab and rituximab, which have all shown promising results. However, the monoclonal antibodies generally have a less favourable safety profile and are more expensive than the currently used first-line therapies, IFNß and glatiramer acetate.